OpenURL Connection Search

Select item for more details and to access through your institution.

Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotin.
Published in:
Hematological Oncology, 2023, v. 41, p. 505, doi. 10.1002/hon.3164_373
By:
- Veleanu, L.;
- Tesson, B.;
- Lamant, L.;
- Marçais, A.;
- Bruneau, J.;
- Kaltenbach, S.;
- Brouzes, C.;
- Degoutte, C.;
- Moraly, J.;
- Villarese, P.;
- Lhermitte, L.;
- Latiri, M.;
- Hure, G.;
- Chauchet, A.;
- Delette, C.;
- Grosleron, S.;
- Toussaint, E.;
- Cabrera, Q.;
- Brice, P.;
- Gros, F.
Publication type:
Article
Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients.
Published in:
Hematological Oncology, 2023, v. 41, p. 288, doi. 10.1002/hon.3164_199
By:
- Laurent, C.;
- Trisal, P.;
- Tesson, B.;
- Lesne, B.;
- Van‐Acker, N.;
- Chartier, L.;
- Stokes, M.;
- Huang, C.;
- Huet, S.;
- Morschhauser, F.;
- Gandhi, A. K;
- Xerri, L.
Publication type:
Article
JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS?
Published in:
Hematological Oncology, 2019, v. 37, p. 201, doi. 10.1002/hon.16_2630
By:
- Laurent, C.;
- Nicolae, A.;
- Le Bras, F.;
- Haioun, C.;
- Fataccioli, V.;
- Amara, N.;
- Adélaïde, J.;
- Guille, A.;
- Schiano De Colella, J.;
- Tesson, B.;
- Traverse‐Glehen, A.;
- Chenard, M.;
- Mescam, L.;
- Moreau, A.;
- Chassagne‐Clément, C.;
- Somja, J.;
- Escudié, F.;
- André, M.;
- Martin, N.;
- Hamy‐Petit, A.
Publication type:
Article
JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS?
Published in:
Hematological Oncology, 2019, v. 37, p. 201, doi. 10.1002/hon.16_2630
By:
- Laurent, C.;
- Nicolae, A.;
- Le Bras, F.;
- Haioun, C.;
- Fataccioli, V.;
- Amara, N.;
- Adélaïde, J.;
- Guille, A.;
- Schiano De Colella, J.;
- Tesson, B.;
- Traverse‐Glehen, A.;
- Chenard, M.;
- Mescam, L.;
- Moreau, A.;
- Chassagne‐Clément, C.;
- Somja, J.;
- Escudié, F.;
- André, M.;
- Martin, N.;
- Hamy‐Petit, A.
Publication type:
Article
TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS.
Published in:
Hematological Oncology, 2017, v. 35, p. 160, doi. 10.1002/hon.2438_16
By:
- Ghesquieres, H.;
- Tesson, B.;
- Courtois ‐ Cox, S.;
- Boyault, S.;
- Nicolas ‐ Virelizier, E.;
- Carrere, M.;
- Traverse ‐ Glehen, A.;
- Perrin, C.;
- Chassagne ‐ Clement, C.;
- Jouanneau, E.;
- Salles, G.;
- Honnorat, J.;
- Blay, J.;
- Meyronet, D.
Publication type:
Article
GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 113, doi. 10.1002/hon.2437_103
By:
- Huet, S.;
- Tesson, B.;
- Jais, J.;
- Feldman, A.L.;
- Magnano, L.;
- Thomas, E.;
- Traverse ‐ Glehen, A.;
- Albaud, B.;
- Xerri, L.;
- Ansell, S.;
- Tarte, K.;
- Boyault, S.;
- Haioun, C.;
- Link, B.;
- Feugier, P.;
- Lopez ‐ Guillermo, A.;
- Brice, P.;
- Hayette, S.;
- Jardin, F.;
- Offner, F.
Publication type:
Article
EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 96, doi. 10.1002/hon.2437_85
By:
- Huet, S.;
- Szafer ‐ Glusman, E.;
- Xerri, L.;
- Bolen, C.;
- Punnoose, E.;
- Tonon, L.;
- Tilly, H.;
- Brice, P.;
- Feugier, P.;
- Tesson, B.;
- Viari, A.;
- Venstrom, J.M.;
- Salles, G.
Publication type:
Article

Found: 7

Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotin.

Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients.

JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS?

JAK‐STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI‐ALCL PATHOGENESIS?

TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS.

GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.

EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL.